Published in Cancer on December 15, 2008
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
Calibration of disease simulation model using an engineering approach. Value Health (2009) 1.27
Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model. Bioinformatics (2009) 1.10
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Chapter 13: CISNET lung models: comparison of model assumptions and model structures. Risk Anal (2012) 0.95
Chapter 1:The impact of the reduction in tobacco smoking on U.S. lung cancer mortality, 1975-2000: an introduction to the problem. Risk Anal (2012) 0.83
Using radiation risk models in cancer screening simulations: important assumptions and effects on outcome projections. Radiology (2012) 0.81
Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer. AJR Am J Roentgenol (2013) 0.78
Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. Cancer (2015) 0.77
Calibration of disease simulation model using an engineering approach. Value Health (2009) 0.76
Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach. PLoS One (2017) 0.75
Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study. BMJ Open (2016) 0.75
Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med (2006) 19.06
Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet (1999) 13.67
Verification, validation, and confirmation of numerical models in the Earth sciences. Science (1994) 8.94
Enthusiasm for cancer screening in the United States. JAMA (2004) 8.22
Computed tomography screening and lung cancer outcomes. JAMA (2007) 8.01
Cost-effectiveness of screening for colorectal cancer in the general population. JAMA (2000) 5.88
Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med (2002) 5.10
Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA (2003) 4.81
Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med (2007) 4.68
Gains in life expectancy from medical interventions--standardizing data on outcomes. N Engl J Med (1998) 4.47
CT screening for lung cancer: five-year prospective experience. Radiology (2005) 4.33
Lung cancer incidence in never smokers. J Clin Oncol (2007) 3.20
Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology (2002) 2.92
Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer (2007) 2.85
The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet (1980) 2.81
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst (2006) 2.66
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA (2000) 2.58
Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med (2004) 2.53
Community intervention trial for smoking cessation (COMMIT): II. Changes in adult cigarette smoking prevalence. Am J Public Health (1995) 2.38
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Smoking cessation during previous year among adults--United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep (1993) 2.26
Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer (2007) 1.68
Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. Thorax (2006) 1.63
Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics (2006) 1.58
Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography. Int J Cancer (2008) 1.54
Smoking cessation following CT screening for early detection of lung cancer. Prev Med (2001) 1.54
Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer (2005) 1.51
The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res (2004) 1.39
The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest (2003) 1.38
Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis. Med Decis Making (2006) 1.14
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. Radiology (2008) 1.13
Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol (2007) 1.09
Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax (2008) 1.05
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Simulation modeling of outcomes and cost effectiveness. Hematol Oncol Clin North Am (2000) 1.00
Examining the effects of false positive lung cancer screening results on subsequent lung cancer screening adherence. Cancer Epidemiol Biomarkers Prev (2003) 0.92
Factors determining early adherence to a lung cancer screening protocol. Eur Respir J (2007) 0.85
Economic considerations in the management of mild hypertension. Ann N Y Acad Sci (1978) 0.85
Modelling for cost-effectiveness analysis. Stat Med (1999) 0.81
A critique of hypertension treatment trials and of their evaluation. J Eval Clin Pract (2001) 0.78
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol (2004) 7.45
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol (2008) 5.61
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology (2003) 5.42
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res (2004) 5.23
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 4.99
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med (2012) 4.72
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res (2010) 4.51
Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol (2003) 4.50
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA (2004) 4.36
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
Small-cell lung cancer. Lancet (2005) 3.98
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol (2007) 3.50
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol (2010) 2.97
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol (2005) 2.88
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care (2005) 2.75
Paraesophageal hernias: operation or observation? Ann Surg (2002) 2.71
Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst (2002) 2.71
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res (2006) 2.68
Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 2.53
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol (2008) 2.51
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Utilization of diagnostic medical imaging: comparison of radiologist referral versus same-specialty referral. Radiology (2007) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res (2007) 2.45
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37